Nintedanib targets TGF-β, a profibrotic cytokine that is involved in fibrotic tissue remodeling in asthma, and other fibrotic diseases, and inhibits fibroblast proliferation induced by stimuli, such as PDGF, FGF, VEGF, and serum [6]. Here, TGFB1 is linked to asthma.